Senseonics to Showcase Eversense 365 Data and Strategy at ADA 2026
Event summary
- Senseonics will host an analyst event on June 6, 2026, during ADA 2026 to discuss Eversense 365 commercial progress, including European launch and integration with Sequel twiist pump.
- Oral presentation on June 6, 2026, will present real-world evidence of Eversense 365's performance in open and closed loop systems.
- Dr. David T. Ahn and Senseonics management will provide updates on clinical data, financials, and pipeline development (Gemini and Freedom programs).
- Eversense 365 is the only implantable CGM system offering up to 365 days of continuous glucose monitoring.
The big picture
Senseonics is positioning Eversense 365 as a differentiated CGM solution in a market increasingly dominated by short-term wearable devices. The focus on real-world evidence and commercial expansion comes as implantable CGMs gain traction among patients seeking longer-term monitoring solutions. Success hinges on demonstrating superior performance metrics and seamless integration with existing diabetes management systems.
What we're watching
- Commercial Execution
- Whether Senseonics can successfully scale Eversense 365's European launch and integration with Sequel twiist pump.
- Regulatory Dynamics
- The pace at which real-world evidence from Eversense 365 could influence broader CGM market adoption.
- Pipeline Development
- How progress on Gemini and Freedom programs will impact Senseonics' long-term competitive positioning.